Keita Nakanishi

Discovery of Ipragliflozin (ASP1941): A novel C-glucoside with benzothiophene structure as a potent and selective sodium glucose co-transporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes mellitus

Masakazu Imamura, Keita Nakanishi, Takayuki Suzuki et al. · Bioorganic & Medicinal Chemistry · 2012 · 132 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +15

Clinical and Genetic Characteristics in Patients With Gitelman Syndrome

Junya Fujimura, Kandai Nozu, Tomohiko Yamamura et al. · Kidney International Reports · 2018 · 75 citations · Full text

Life Sciences, Endocrinology, Genetics +11

Common risk variants in NPHS1 and TNFSF15 are associated with childhood steroid-sensitive nephrotic syndrome

Xiaoyuan Jia, Tomohiko Yamamura, Rasheed Gbadegesin et al. · Kidney International · 2020 · 73 citations · Full text

Life Sciences, Genetics, Molecular Genetics +17

Detection of Splicing Abnormalities and Genotype-Phenotype Correlation in X-linked Alport Syndrome

Tomoko Horinouchi, Kandai Nozu, Tomohiko Yamamura et al. · Journal of the American Society of Nephrology · 2018 · 65 citations · Full text

Life Sciences, Genetics, Molecular Genetics +16

Synthesis and biological evaluation of C-glucosides with azulene rings as selective SGLT2 inhibitors for the treatment of type 2 diabetes mellitus: Discovery of YM543

Kazuhiro Ikegai, Masakazu Imamura, Takayuki Suzuki et al. · Bioorganic & Medicinal Chemistry · 2013 · 52 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +14